Company profile

Tonix Pharmaceuticals

Industry
Pharmaceutical Manufacturing
Employees
180
Headquarters
Berkeley Heights, New Jersey
Founded
2007
LinkedIn followers
23,677
Office locations
1

Tonix Pharmaceuticals company summary

Tonix Pharmaceuticals is a company in the Pharmaceutical Manufacturing industry, headquartered in Berkeley Heights, New Jersey, founded in 2007. On LinkedIn the company has around 180 employees and 23,677 followers.

What technology does Tonix Pharmaceuticals use?

No technologies detected yet. Warmrank rechecks company websites on a rolling basis.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases where there exists high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com. *Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Where is Tonix Pharmaceuticals located?

Tonix Pharmaceuticals lists 1 location.

Berkeley Heights, New Jersey, USHQ
200 Connell Dr

Compare companies similar to Tonix Pharmaceuticals

More companies in Pharmaceutical Manufacturing.

CompanyIndustryEmployeesFoundedHeadquarters
Tonix Pharmaceuticals
tonixpharma.com
Pharmaceutical Manufacturing1802007Berkeley Heights, New Jersey
Pharmaceutical Manufacturing108,102-New York, New York
Sanofi
sanofi.com
Pharmaceutical Manufacturing93,352-Paris, France, FR
GSK
gsk.com
Pharmaceutical Manufacturing92,179-London, England
Novartis España
novartis.com
Pharmaceutical Manufacturing85,373-Basel, Baselstadt
AstraZeneca
astrazeneca.com
Pharmaceutical Manufacturing80,667-Cambridge, Cambridgeshire, GB
Pharmaceutical Manufacturing57,202-Indianapolis, Indiana
Merck
merck.us
Pharmaceutical Manufacturing44,794-Rahway, New Jersey
SUN PHARMA
sunpharma.com
Pharmaceutical Manufacturing47,7641983Mumbai, Maharastra
Boehringer Ingelheim
boehringer-ingelheim.com
Pharmaceutical Manufacturing47,150-Ingelheim am Rhein, Rhineland-Palatinate
Cipla
cipla.com
Pharmaceutical Manufacturing51,911-Mumbai, Maharashtra

Frequently asked questions about Tonix Pharmaceuticals

What does Tonix Pharmaceuticals do?

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases where there exists high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com. *Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals has around 180 employees on LinkedIn.

Where is Tonix Pharmaceuticals headquartered?

Tonix Pharmaceuticals is headquartered in Berkeley Heights, New Jersey.

When was Tonix Pharmaceuticals founded?

Tonix Pharmaceuticals was founded in 2007.

Build a lead list from companies like Tonix Pharmaceuticals

Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.